Johnson & Johnson (JNJ): FY24 Q4 earnings call, Jan 22, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jan 22, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Procedure”; 5 quoted, at least 25 words apart.
…our VELYS robotic assisted solution for the use in Unicompartmental Knee Arthroplasty procedures as well as an expanded FDA indication for Impella heart pumps to…
…In Cardiovascular, electrophysiology delivered growth of 7.3%. Performance was driven by global procedure growth, new product uptake and commercial execution, partially offset by competitive PFA…
…throughout the year. As we've said before, we continue to expect normalized procedure volume and seasonality. Regarding the P&L, it is important to consider one-time…
…our end markets growing roughly 5% to 7%. As we look at procedures within the year to come, we believe that they have, for the…
…orthopedic procedures. We believe that for the most part around the world, procedures have normalized to pre-COVID levels and we expect the same as we…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-01-22:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-01-22:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP